Multiple Myeloma, Refractory Clinical Trials
3 recruiting trials for Multiple Myeloma, Refractory. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Multiple Myeloma, Refractory clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 67% (2 studies); the largest phase groups are Phase 2: 2, Phase 1: 1.
Research is led by Duke University (1), Luminary Therapeutics (1), Oncotherapeutics (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Selinexor 40 mg (drug, 1 trial), followed by Autologous CAR-T cell therapy expressing the BAFF-ligand., Venetoclax.
Track Multiple Myeloma, Refractory trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory...
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become...
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Multiple Myeloma, Refractory, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Multiple Myeloma, Refractory, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Multiple Myeloma, Refractory, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.